These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2835679)

  • 1. Absence of antibody response to simian virus 40 after inoculation with killed-poliovirus vaccine of mothers of offspring with neurologic tumors.
    Rosa FW; Sever JL; Madden DL
    N Engl J Med; 1988 Jun; 318(22):1469. PubMed ID: 2835679
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurologic tumors in offspring after inoculation of mothers with killed-poliovirus vaccine.
    Melnick JL; Butel JS
    N Engl J Med; 1988 Nov; 319(18):1226. PubMed ID: 2845271
    [No Abstract]   [Full Text] [Related]  

  • 3. Poliovirus vaccination during pregnancy, maternal seroconversion to simian virus 40, and risk of childhood cancer.
    Engels EA; Chen J; Viscidi RP; Shah KV; Daniel RW; Chatterjee N; Klebanoff MA
    Am J Epidemiol; 2004 Aug; 160(4):306-16. PubMed ID: 15286015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SV40 and SV40-like viruses as possible risk factors.
    Geissler E
    Arch Geschwulstforsch; 1983; 53(3):217-26. PubMed ID: 6311136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for SV40 in human cancer?
    Poulin DL; DeCaprio JA
    J Clin Oncol; 2006 Sep; 24(26):4356-65. PubMed ID: 16963733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serologic evidence for a simian-virus-40-like infection of man.
    Shah KV; McCrumb FR; Daniel RW; Ozer HL
    J Natl Cancer Inst; 1972 Feb; 48(2):557-61. PubMed ID: 4347041
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral polio vaccine and human cancer: a reassessment of SV40 as a contaminant based upon legal documents.
    Kops SP
    Anticancer Res; 2000; 20(6C):4745-9. PubMed ID: 11205211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poliovirus antibody status after vaccination with trivalent oral vaccine.
    Clara R; Deprettere A; van der Berghe D; Pattyn S
    Acta Paediatr Belg; 1976; 29(4):245-51. PubMed ID: 192040
    [No Abstract]   [Full Text] [Related]  

  • 9. Sera collected before introduction of contaminated polio vaccine contain antibodies against SV40.
    Geissler E; Konzer P; Scherneck S; Zimmermann W
    Acta Virol; 1985 Sep; 29(5):420-3. PubMed ID: 2866697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live oral poliovirus vaccines do not contain detectable simian virus 40 (SV40) DNA.
    Sierra-Honigmann A; Krause PR
    Biologicals; 2000 Mar; 28(1):1-4. PubMed ID: 10799049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates.
    Mortimer EA; Lepow ML; Gold E; Robbins FC; Burton GJ; Fraumeni JF
    N Engl J Med; 1981 Dec; 305(25):1517-8. PubMed ID: 6272114
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistence of poliovirus neutralizing antibodies eight years after immunization with live, attenuated-virus vaccine.
    Rousseau WE; Noble GR; Tegtmeier GE; Jordan MC; Chin TD
    N Engl J Med; 1973 Dec; 289(25):1357-9. PubMed ID: 4356637
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
    Horaud F
    Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibodies to SV40 in sera from humans and macaques.
    Minor P; Pipkin PA
    Dev Biol (Basel); 2006; 123():99-107; discussion 119-32. PubMed ID: 16566439
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunization against poliomyelitis: risk/benefit/cost in a changing context.
    Salk J
    Dev Biol Stand; 1979; 43():151-7. PubMed ID: 230106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live poliovirus vaccine in patients with chronic glomerulonephritis: effects on renal function and specific antibody response.
    Pozzetto B; Genin C; Gaudin OG; Berthoux FC; Alloin B; Laurent B; Ros A
    Clin Nephrol; 1987 Oct; 28(4):194-8. PubMed ID: 3690900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives.
    Goldblum N; Kra-Oz Z; Swartz T
    Dev Biol Stand; 1979; 43():173-7. PubMed ID: 230108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
    Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
    J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium.
    Lamy ME; Cornu C; Desmyter J
    Dev Biol Stand; 1979; 43():207-13. PubMed ID: 230111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SV40 and human brain tumors.
    Geissler E; Staneczek W
    Arch Geschwulstforsch; 1988; 58(2):129-34. PubMed ID: 2837160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.